The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -23.75 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -3.73 — no flag raisedOK
- Earnings quality 62/100 — worth a closer lookWatch
Leadership changes
From Inmune Bio, Inc.'s own filings, the day they're filed.
- Edgardo Baracchini · directors · departureeff. 2024-07-05
- Involuntary Termination · departure
Latest filings
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-07-31
- 8-K · Company announcement2026-07-01
- 8-K · Company announcement2026-06-23
- 8-K · Company announcement2026-06-17
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Inmune Bio, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Inmune Bio, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.